Hayley Belli

Real-World Data Collected from Expanded Access Programs

Since the pandemic, the US Food and Drug Administration’s Expanded Access pathway has been featured in headlines as a mechanism by which unapproved but potentially beneficial treatments were given to patients outside of randomized clinical trials.